Exact Sciences Corp ((EXAS)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst ...

Exact Science’s Michelle Beidelschies, PhD, reveals how a multi-biomarker class multi-cancer early detection test (MCED) blood test can help health systems expand detection across more cancers earlier ...

lab technician handling blood tests Results from the PATHFINDER study suggest that MCED testing is feasible in practice, but more research is needed to assess its clinical utility. Results from the ...

As multi-cancer early detection (MCED) testing gains momentum, experts are honing their focus on what comes next for patients with a positive MCED test result. Understanding the diagnostic pathways ...

Multicancer early detection testing results in extended life-years and reduced cancer treatment costs through earlier diagnosis, leading to a cost-effective option in cancer screening. Objectives: ...

In the United States, healthcare providers routinely screen for four different types of cancer: breast, colorectal, cervical, and high-risk lung cancer. Unfortunately, these screenings only catch 14% ...

Screening, diagnosing and curing cancer at its earliest, most treatable stages has become a welcome and regular occurrence for radiation oncologist Nima Nabavizadeh, M.D. This has been made possible ...

A single blood test, designed to pick up chemical signals indicative of the presence of many different types of cancer, could potentially thwart progression to advanced disease while the malignancy is ...

Breakthroughs in early detection of cancer offer increasing hope for better outcomes and longer lives for individuals affected by malignancies. This year’s American Society of Clinical Oncology annual ...

The cumulative cancer incidence after a false-positive MCED test result was 1.0% at 1 year and 3.4% at 2 years, 3 years, and 4 years. Patients with a false-positive result from the multicancer early ...

Exact Sciences Corporation EXAS has launched the Cancerguard test, a new multi-cancer early detection (MCED) blood test now offered as a laboratory-developed test (LDT) in the United States.